All In Biotech

Drug Trial Radar · NCT07699471

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 26, 2026

Primary completion

Jan 2028

Study completion Aug 2029

Sponsor

Lead sponsor
MBX BiosciencesIndustry
Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).

Conditions

  • Hypoparathyroidism

Interventions

  • CanvuparatideDrug

    • Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.

  • PlaceboOther

    • Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.Time frame: 26 Weeks

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • MBX Biosciences Investigational Site

    Sacramento, California · Recruiting

  • MBX Biosciences Investigational Site

    Aurora, Colorado · Recruiting

  • MBX Biosciences Investigational Site

    Englewood, Colorado · Recruiting

  • MBX Biosciences Investigational Site

    Homestead, Florida · Recruiting

  • MBX Biosciences Investigational Site

    Lawrenceville, Georgia · Recruiting

  • MBX Biosciences Investigational Site

    Metairie, Louisiana · Recruiting

  • MBX Biosciences Investigational Site

    Jackson, Mississippi · Recruiting

  • MBX Biosciences Investigational Site

    Omaha, Nebraska · Recruiting

  • MBX Biosciences Investigational Site

    Las Vegas, Nevada · Recruiting

  • MBX Biosciences Investigational Site

    Reno, Nevada · Recruiting

  • MBX Biosciences Investigational Site

    Albany, New York · Recruiting

  • MBX Biosciences Investigational Site

    Syracuse, New York · Recruiting

  • MBX Biosciences Investigational Site

    The Bronx, New York · Recruiting

  • MBX Biosciences Investigational Site

    Greenville, North Carolina · Recruiting

  • MBX Biosciences Investigational Site

    Columbus, Ohio · Recruiting

  • MBX Biosciences Investigational Site

    Summerville, South Carolina · Recruiting

  • MBX Biosciences Investigational Site

    Dallas, Texas · Recruiting

  • MBX Biosciences Investigational Site

    Edinburg, Texas · Recruiting

  • MBX Biosciences Investigational Site

    Houston, Texas · Recruiting

  • MBX Biosciences Investigational Site

    Round Rock, Texas · Recruiting

  • MBX Biosciences Investigational Site

    Shavano Park, Texas · Recruiting

  • MBX Biosciences Investigational Site

    Weslaco, Texas · Recruiting

  • MBX Biosciences Investigational Site

    Spokane, Washington · Recruiting

  • MBX Biosciences Investigational Site

    Madison, Wisconsin · Recruiting

  • MBX Biosciences Investigational Site

    Buenos Aires, Argentina · Recruiting

  • MBX Biosciences Investigational Site

    Rosario, Argentina · Recruiting

  • MBX Biosciences Investigational Site

    San Miguel de Tucumán, Argentina · Recruiting

  • MBX Biosciences Investigational Site

    Oakville, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.